Mergers & Acquisitions ·
Lantheus Holdings reported second quarter 2026 financial results with worldwide revenue of $388.2 million, a 2.7%…
LNTHLantheus Holdings, Inc.
Lantheus Holdings reported second quarter 2026 financial results with worldwide revenue of $388.2 million, a 2.7% increase from the prior year period. GAAP fully diluted earnings per share were $1.11, while adjusted fully diluted EPS was $1.55. The company suspended its full-year 2026 financial guidance and will not host an earnings conference call due to pending M&A activity. On August 3, 2026, Lantheus entered into a definitive agreement to merge with Curium in an all-cash transaction valued at up to approximately $8.0 billion. Under the deal, shareholders will receive $102.50 per share plus Contingent Value Rights providing for up to $12.00 per share based on commercial milestones through 2030. The combined entity aims to create a radiopharmaceutical company spanning diagnostics and therapeutics across more than 70 countries. Lantheus is a leading radiopharmaceutical-focused company delivering diagnostic and therapeutic solutions.